## Treatment and Clinical Features of Gonorrhea and Chlamydia ### Why Option D Is the FALSE Statement (Correct Answer for EXCEPT) **High-Yield:** Option D states that **Ceftriaxone 250 mg IM single dose** is the current first-line treatment for uncomplicated urogenital gonorrhea in India. This is **outdated and incorrect** per current guidelines. - The **CDC 2021 STI Treatment Guidelines** updated the recommended dose of ceftriaxone for uncomplicated gonorrhea from **250 mg to 500 mg IM** (or 1 g IM if body weight ≥150 kg). This change was made due to concerns about emerging cephalosporin resistance and to ensure adequate tissue concentrations. - The **WHO 2016 guidelines** and subsequent updates also recommend higher doses of ceftriaxone. - In India, the **National AIDS Control Organisation (NACO)** guidelines have similarly moved toward higher ceftriaxone doses in line with global recommendations. - Therefore, **250 mg IM** is no longer the standard first-line dose; **500 mg IM** is the current recommendation. Option D is FALSE. **Clinical Pearl:** The dose escalation from 250 mg to 500 mg ceftriaxone reflects the global trend of increasing minimum inhibitory concentrations (MICs) for *N. gonorrhoeae*, necessitating higher doses to maintain efficacy [Harrison's Principles of Internal Medicine, 21e, Ch. 137]. --- ### Why the Other Options Are TRUE **Option A — Post-Gonococcal Urethritis (PGU):** PGU (persistent urethritis after successful gonorrhea treatment) occurs in 20–40% of cases and is most commonly caused by concurrent *Chlamydia trachomatis* infection (40–60% of PGU cases). This is the rationale for dual therapy. ✅ TRUE [Harrison 21e, Ch. 137] **Option B — Fluoroquinolone Resistance:** Fluoroquinolones (ciprofloxacin, ofloxacin) are no longer recommended for gonorrhea treatment globally, including India, due to resistance rates exceeding 50% in many regions. This is well-established since the mid-2000s. ✅ TRUE [Harrison 21e, Ch. 137; Park's Textbook of Preventive and Social Medicine, 26e] **Option C — Azithromycin for Chlamydia:** Single-dose azithromycin 1 g orally achieves cure rates >95% in uncomplicated chlamydial urethritis and remains an **acceptable** treatment option (particularly in pregnancy where doxycycline is contraindicated), even though 7-day doxycycline is now preferred as first-line per 2021 CDC guidelines. The statement that it "achieves cure rates >95%" is factually supported in the literature. ✅ TRUE (or at minimum, not unambiguously false) --- ### Treatment Summary Table | Organism | Current First-Line | Alternative | Duration | |---|---|---|---| | **N. gonorrhoeae** | Ceftriaxone **500 mg** IM × 1 | Cefixime 800 mg PO × 1 | Single dose | | **C. trachomatis** | Doxycycline 100 mg BD | Azithromycin 1 g × 1 (acceptable) | 7 days | | **Dual therapy** | Ceftriaxone 500 mg IM + Doxycycline 100 mg BD | — | 7 days | **Key Point:** The shift from 250 mg to 500 mg ceftriaxone for gonorrhea is a high-yield exam fact reflecting updated 2021 CDC/WHO guidelines. Option D's use of "250 mg" makes it the FALSE statement in this EXCEPT question.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.